Treatment of metastatic renal cell carcinoma and renal pelvic cancer

Clinical and Experimental Nephrology

Volumn 15, Issue 3, 2011, Pages 331-338

  Tanji, Nozomu ^a   Yokoyama, Masayoshi ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Combination of gemcitabine and cisplatin; Molecular targeted drug; Renal cell carcinoma; Renal pelvic cancer

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DOXORUBICIN; EVEROLIMUS; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 12; LEVOTHYROXINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VINBLASTINE; VON HIPPEL LINDAU PROTEIN;

ABNORMAL LABORATORY RESULT; ANEMIA; ANOREXIA; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CELL PROLIFERATION; CHILL; CLEAR CELL CARCINOMA; CONGESTIVE HEART FAILURE; COUGHING; DESQUAMATION; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DYSPNEA; FATIGUE; GENE MUTATION; GENE SILENCING; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INFECTION; KIDNEY CARCINOMA; KIDNEY PELVIS CANCER; LEUKOPENIA; LUNG DISEASE; LYMPHOCYTOPENIA; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MUCOSAL DISEASE; NAUSEA; NEPHROURETERECTOMY; NEUTROPENIA; NEUTROPHIL COUNT; ORAL MUCOSAL DISEASE; OVERALL SURVIVAL; PATHOGENESIS; PERIPHERAL EDEMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TORSADE DES POINTES; TRANSITIONAL CELL CARCINOMA; VON HIPPEL LINDAU DISEASE; WEIGHT REDUCTION; WHEEZING;

BENZENESULFONATES; CARCINOMA, RENAL CELL; CISPLATIN; DEOXYCYTIDINE; HUMANS; INDOLES; KIDNEY NEOPLASMS; KIDNEY PELVIS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; SIROLIMUS;

EID: 79959269606     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0438-9     Document Type: Review

References (65)

1. Knox M, Colli JL. Characterizing changes in kidney and renal pelvis cancer incidence from 1998 to 2006 in the United States. Int Urol Nephrol. 2011. doi:10.1007/s11255-010-9827-3.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
3. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245-57.
4. Guinan PD, Vogelzang NJ, Fregman AM, Chmiel JS, Sylvester JL, Sener SF, et al. Renal cell carcinoma: tumor size, stage and survival. Members of the Cancer incidence and End Results Committee. J Urol. 1995;153:901-3.
5. Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol. 2006;24:5584-92.
6. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin N Am. 1993;20:283-95. (Pubitemid 23154478)
7. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6:S55-7.
8. Inglese M. Von Hippel-Lindaw disease: an overview. Nephrol Nurs J. 2007;34:390-3.
9. Choyke PI, Glenn GM, Walther MC, Zbar B, Linehan WM. Hereditary renal cancers. Radiology. 2003;226:33-46. (Pubitemid 36163905)
10. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer. 1998;22:200-9. (Pubitemid 28262196)
11. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007;13:S758-63.
12. Land SC, Tee AR. Hypoxia-inducible factor 1 alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem. 2007;282:20534-43. (Pubitemid 47100043)
13. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12:426-37. (Pubitemid 46698720)
14. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-12. (Pubitemid 46630627)
15. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34. (Pubitemid 46089673)
16. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudara S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312-8.
17. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol. 2007;37:755-62. (Pubitemid 350120299)
18. Motzer RJ, Agarwal N, Beard C, Bolfer GB, Boston B, Carducci MA, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Cancer Netw. 2009;7:618-30.
19. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, et al. Guidelines on renal cell carcinoma. 2009. http://www.uroweb.org/ fileadmin/tx-eauguidelines/2009/Full/RCC.pdf.
20. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1280-9.
21. Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007;25:3296-301. (Pubitemid 47325615)
22. Niwakawa M, Hashine K, Yamaguchi R, Fujii H, Hamamoto Y, Tanigawa T, et al. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. Invest New Drugs. 2011 (Epub ahead of print).
23. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884-96. (Pubitemid 350002890)
24. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:4-5.
25. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24. (Pubitemid 46630489)
26. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-24. (Pubitemid 43854967)
27. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24. (Pubitemid 46089672)
28. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-90.
29. National Institute for Health and Clinical Excellence. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. NICE Technology Appraisal Guidance 169, March 2009. http://www.nice.org.uk/TA169.
30. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26:127-31.
31. Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, et al. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol. 2010;40:980-5.
32. Tomita Y, Shinohara N, Yuasa T, Fujimoto H, Niwakawa M, Mugita S, et al. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2010;40:1166-72.
33. Lee S, Chung HC, Mainwaring P, Ng C, Chang JWC, Kwong P, et al. An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma. Eur J Cancer Suppl. 2009;7:428.
34. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53:917-30.
35. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81-3.
36. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17:351-5. (Pubitemid 46776140)
37. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145:660-4. (Pubitemid 46768841)
38. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92:3531-4. (Pubitemid 47435331)
39. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009;6:219-28.
40. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007;13:758s-63s.
41. Skotnicki JS, Leone CL, Smith AL. Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779. Clin Cancer Res. 2001;7:3749S-50S.
42. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-18. (Pubitemid 41103603)
43. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Global ARCC Trial, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-81. (Pubitemid 46849157)
44. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009;115:2438-46.
45. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet. 2008;372:449-56.
46. Motzer RJ, Escudier B, Oudard S, Hutoson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256-65.
47. Genega EM, Porter CR. Urothelial neoplasms of the kidney and ureter. An epidemiologic, pathologic, and clinical review. Am J Clin Pathol. 2002;117:S36-48.
48. Hall MC, Womack S, Sagalowsky AI, Carmodi T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: 30-year experience in 252 patients. Urology. 1998;52:594-601. (Pubitemid 28440164)
49. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115:1224-33.
50. Raman JD, Scherr DS. Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol. 2007;4:432-43. (Pubitemid 47244090)
51. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989;64:2448-58.
52. Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol. 1989;142:289-92. (Pubitemid 19197098)
53. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-81. (Pubitemid 29470648)
54. Sternberg CN, de Mulder PH, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638-46. (Pubitemid 32441368)
55. Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42:50-4. (Pubitemid 41814532)
56. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, et al. Evaluation of the anti-tumor activity of gemcitabine (2′,2′- difluoro-2′-deoxycytidine). Cancer Res. 1990;50:4417-22. (Pubitemid 20225688)
57. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-8.
58. Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer. 1998;34:1208-12. (Pubitemid 28342111)
59. Stadler WM, Kuzel T, Roth B, raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394-8. (Pubitemid 27485860)
60. Akaza H, Naito S, Usami M, Miki T, Miyanaga N, Taniai H, et al. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin-containing therapy: a Japanese experience. Jpn J Clin Oncol. 2007;37:201-6. (Pubitemid 47090695)
61. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18:1921-7. (Pubitemid 30261930)
62. Moore MJ, Winquist E, Murray N, Tannock IF, Huan S, Benneti K, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol. 1999;17:2876-81. (Pubitemid 29415247)
63. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-77.
64. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602-8. (Pubitemid 46224062)
65. Tanji N, Ozawa A, Miura N, Yanagihara Y, Sasaki T, Nishida T, et al. Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas. Int J Clin Oncol. 2010;15:369-75.